scholarly journals Strategy and choice criteria’s of initial disturbances of brain circulation in family physician’s practice

2021 ◽  
pp. 12-15
Author(s):  
S. G. Burchinsky
Keyword(s):  
Clinical Efficacy ◽  
Brain Ischemia ◽  
Mechanisms Of Action ◽  
Point Of View ◽  
Clinical Use ◽  
Brain Circulation ◽  
Pathological Changes ◽  
Main Attention ◽  
Cerebrovascular Pathology ◽  
Ethyl Methyl

In the present paper a modern sights to manifestations of initial stages of brain ischemia and its role in damage of CNS in cerebrovascular pathology have been looked. Based on this point of view, the requirements to choice of optimal pharmacological strategy concerning correction of brain pathological changes during ischemia, and particularly neurometabolic pharmacotherapy’ advantages have been analyzed. A basic goals of clinical use of neuroprotection’s strategy in generally, and particularly neurometabolic pharmacotherapy have been looked. A main attention paid to mechanisms of action and peculiarities of clinical use of drug Dinar (ethyl-methyl-hydroxypiridine succinat) and its possibilities in plane to realization of pathogenetically grounding neurometabolic pharmacotherapy of initial stages of cerebrovascular pathology. A clinical efficacy of Dinar and its safety characteristics have been looked in detail.

Strategy of Neurometabolic Pharmacotherapy: Targets, Problems, Instruments

2016 ◽  
pp. 50-54
Author(s):  
Serhii Burchinsky
Keyword(s):  
Clinical Practice ◽  
Clinical Efficacy ◽  
Mechanisms Of Action ◽  
Point Of View ◽  
Clinical Use ◽  
Main Attention ◽  
Ethyl Methyl ◽  
Neuronal Metabolism

In the present paper a modern sights to problem of neurometabolic pharmacotherapy looking on correction of neuronal metabolism in clinical practice have been looked. Based on this point of view, the requirements to choice of optimal pharmacological tool of this strategy have been analyzed. A main attention paid to mechanisms of action and peculiarities of clinical use of drug Mexiprim (ethyl-methyl-hydroxypiridine succinat) with unique pharmacological and clinical properties, that make possible to realize the strategy of pathogenetically grounded neurometabolic pharmacotherapy in treatment of cerebrovascular disturbances, and other forms of pathology. A clinical efficacy of Mexiprim and its safety characteristics have been analyzed.

scholarly journals Pain, depression and anxiety: is there a light at the end of the tunnel?

2021 ◽  
pp. 14-18
Author(s):  
S. G. Burchinsky
Keyword(s):  
Anxiety Disorders ◽  
Mechanisms Of Action ◽  
Point Of View ◽  
Pharmacological Properties ◽  
Clinical Use ◽  
Depression And Anxiety ◽  
Main Attention ◽  
Ionic Permeability ◽  
Psychogenic Pain ◽  
Mechanisms Of Development

In the present paper a modern sights to problem of chronic psychogenic pain and its relation to depressive and anxiety disorders have been looked. Based on this point of view, the requirements to choice of optimal pharmacological tool within complex therapy of psychogenic pain, depression and anxiety have been analyzed. A main attention paid to mechanisms of action and peculiarities of clinical use of drugs: duloxetine (Revival) – antidepressant from SNRI group with unique mechanisms of action and clinico-pharmacological properties, which make possible to realize the on-time impact on the mechanisms of development of depression and psychogenic pain; and pregabaline (Ligato) – drug from the anticonvulsants group, which influenced on universal mechanisms of cell ionic permeability at anxiety disorders and psychogenic pain. A clinical efficacy of duloxetine (Revival) and pregabaline (Ligato), its safety characteristics, and recommendations of practical use have been looked in detail.

scholarly journals Strategy of membrane protection in pharmacotherapy of vascular cognitive impairment

2021 ◽  
Vol 16 (8) ◽  
pp. 37-42
Author(s):  
S.G. Burchinsky
Keyword(s):  
Cognitive Impairment ◽  
Cerebrovascular Disorders ◽  
The Elderly ◽  
Vascular Cognitive Impairment ◽  
Mechanisms Of Action ◽  
Point Of View ◽  
Clinical Use ◽  
Mild Cognitive Impairment Syndrome ◽  
Selection Of ◽  
Membrane Protection

The article considers modern views on the problem of vascular cognitive dysfunction, in particular, on the nature and options of treatment of mild cognitive impairment syndrome as one of the most common forms of cognitive decline in the elderly and senile patients. From this point of view, the requirements for the selection of the optimal pharmacological tool for pharmacotherapy and pharmacoprophylaxis of this syndrome, especially the strategy of membrane protection, are analyzed. Particular attention is paid to the mechanisms of action and features of clinical use of Lira (citicoline) — a drug with unique clinical and pharmacological properties that allow implementing a strategy of pathogenetically sound neuro- and geroprotective pharmacotherapy in cerebrovascular disorders. Mechanisms of action, clinical efficacy of Lira (citicoline), safety characteristics and recommendations for practical use of the drug are considered in detail.

scholarly journals Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy

2021 ◽  
Vol 22 (8) ◽  
pp. 4203
Author(s):  
Giorgio Valabrega ◽  
Giulia Scotto ◽  
Valentina Tuninetti ◽  
Arianna Pani ◽  
Francesco Scaglione
Keyword(s):  
Ovarian Cancer ◽  
Signal Transduction ◽  
Dna Damage ◽  
Chemical Structure ◽  
Parp Inhibitors ◽  
Mechanisms Of Action ◽  
Point Of View ◽  
Safety And Efficacy ◽  
Damage Repair ◽  
Pharmacokinetic Properties

Poly(ADP-ribose) polymerases (PARP) are proteins responsible for DNA damage detection and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for PARP cofactor (NAD+) and trapping PARP on the DNA. In this way, they inhibit single-strand DNA damage repair. These drugs have been approved in recent years for the treatment of ovarian cancer. Although they share some similarities, from the point of view of the chemical structure and pharmacodynamic, pharmacokinetic properties, these drugs also have some substantial differences. These differences may underlie the different safety profiles and activity of PARPi.

Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy

2007 ◽  
Vol 1117 (1) ◽  
pp. 209-257 ◽  
Author(s):  
R. G. G. RUSSELL ◽  
Z. XIA ◽  
J. E. DUNFORD ◽  
U. OPPERMANN ◽  
A. KWAASI ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Mechanisms Of Action

Prospects for immunomodulatory therapy of bronchial asthma

1998 ◽  
Vol 79 (5) ◽  
pp. 388-391
Author(s):  
G. V. Cherepnev ◽  
Y. D. Slabnov ◽  
I. E. Zimakova
Keyword(s):  
Bronchial Asthma ◽  
Russian Federation ◽  
Mechanisms Of Action ◽  
Immunomodulatory Therapy ◽  
Immune Homeostasis ◽  
Clinical Use ◽  
Immunological Reactivity ◽  
The Past ◽  
The Russian Federation ◽  
Pharmacological Correction

The relevance of pharmacological correction of immunological reactivity is obvious: many socially significant diseases are accompanied by an imbalance in immune homeostasis. In the past few years, a number of reviews on the classification and mechanisms of action of immunotropic drugs approved for clinical use in the Russian Federation have been published in the domestic press.

Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

2012 ◽  
Vol 142 (1) ◽  
pp. 15-24 ◽  
Author(s):  
Jens Ingwersen ◽  
Orhan Aktas ◽  
Patrick Kuery ◽  
Bernd Kieseier ◽  
Alexey Boyko ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Efficacy ◽  
Mechanisms Of Action
Sign in / Sign up

Export Citation Format

Share Document